+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Non-melanoma Skin Cancer Market 2018-2022 - Product Image

Global Non-melanoma Skin Cancer Market 2018-2022

  • ID: 4722126
  • Report
  • November 2018
  • Region: Global
  • 103 pages
  • TechNavio
UP TO OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • 3M Pharmaceuticals
  • Bausch Health
  • F. Hoffmann-La Roche
  • Sun Pharmaceuticals
  • MORE
Surgery is considered as the first line curative approach for NMSC, despite the presence of an extensive range of non-surgical treatment modalities. This is because surgery results in the highest cure rate. Surgical treatment provides superior outcomes regarding complete lesion response, clearance of NMSC, cumulative recurrence probabilities compared with cryotherapy, photodynamic therapy, radiotherapy, 5-FU, and imiquimod. The analysts have predicted that the non-melanoma skin cancer market will register a CAGR of almost 6% by 2022.

Market Overview

Increase in incidence of NMSC

The white population in Europe, the US, and Australia are highly affected by NMSC, and the incidence of NMSC is increasing. Globally, NMSC differs significantly. Lower incidence rates are registered in African countries and higher rates are observed in Australia. THE NMSC incidence rate is low in other parts of Europe compare to UK.

Few drugs in pipeline for NMSC

The drug pipeline for NMSC has very few molecules because of the low amount of R&D in this area. Non-disease modifying drugs are under evaluation. Most drugs are being evaluated for palliative care or as an adjuvant therapy. Various studies are being conducted to test newer targeted drugs for the treatment of advanced SCC.

For the detailed list of factors that will drive and challenge the growth of the non-melanoma skin cancer market during the 2018-2022, view this report.

Competitive Landscape

The market appears to be concentrated and with the presence of several companies including Bausch Health and F. Hoffmann-La Roche,, the competitive environment is quite intense. Factors such as the increasing incidence of NMSC and NMSC coverage and support, will provide considerable growth opportunities to non-melanoma skin cancer manufactures. Bausch Health, F. Hoffmann-La Roche, Sun Pharmaceuticals, and 3M Pharmaceuticals are some of the major companies covered in this report.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 3M Pharmaceuticals
  • Bausch Health
  • F. Hoffmann-La Roche
  • Sun Pharmaceuticals
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 05: PIPELINE ANALYSIS
  • NMSC pipeline
PART 06: MARKET SIZING
  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • The threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 08: MARKET SEGMENTATION BY TYPE OF NMSC
  • Segmentation by type of NMSC
  • Comparison by type of NMSC
  • BCC - Market size and forecast 2017-2022
  • SCC - Market size and forecast 2017-2022
  • Market opportunity by type of NMSC
PART 09: MARKET SEGMENTATION BY THERAPY
  • Segmentation by therapy
PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE
  • Geographical Segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Market opportunity
PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 14: MARKET TRENDS
  • Increasing incidence of NMSC
  • Surgery considered as a first-line curative approach for NMSC
  • High off-label use of topical treatments for NMSC
  • Low physician adherence to NMSC diagnostic and treatment guidelines
PART 15: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 16: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bausch Health
  • F. Hoffmann-La Roche
  • Sun Pharmaceuticals
  • 3M Pharmaceuticals
PART 17: APPENDIX
  • List of abbreviations
List of Exhibits
Exhibit 01: Global NMSC market
Exhibit 02: Global oncology market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global - Market size and forecast 2017-2022 ($ mn)
Exhibit 09: Global - Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2017
Exhibit 18: Type of NMSC - Market share 2017-2022 (%)
Exhibit 19: Comparison by type of NMSC
Exhibit 20: BCC - Market size and forecast 2017-2022 ($ mn)
Exhibit 21: BCC - Year-over-year growth 2018-2022 (%)
Exhibit 22: SCC - Market size and forecast 2017-2022 ($ mn)
Exhibit 23: SCC - Year-over-year growth 2018-2022 (%)
Exhibit 24: Market opportunity by type of NMSC
Exhibit 25: Customer landscape
Exhibit 26: Global - Market share by geography 2017-2022 (%)
Exhibit 27: Regional comparison
Exhibit 28: Americas - Market size and forecast 2017-2022 ($ mn)
Exhibit 29: Americas - Year-over-year growth 2018-2022 (%)
Exhibit 30: Top 3 countries in Americas
Exhibit 31: EMEA - Market size and forecast 2017-2022 ($ mn)
Exhibit 32: EMEA - Year-over-year growth 2018-2022 (%)
Exhibit 33: Top 3 countries in EMEA
Exhibit 34: APAC - Market size and forecast 2017-2022 ($ mn)
Exhibit 35: APAC - Year-over-year growth 2018-2022 (%)
Exhibit 36: Top 3 countries in APAC
Exhibit 37: Market opportunity
Exhibit 38: Vendor landscape
Exhibit 39: Landscape disruption
Exhibit 40: Vendors covered
Exhibit 41: Vendor classification
Exhibit 42: Market positioning of vendors
Exhibit 43: Bausch Health - Overview
Exhibit 44: Bausch Health - Business segments
Exhibit 45: Bausch Health - Organizational developments
Exhibit 46: Bausch Health - Geographic focus
Exhibit 47: Bausch Health - Segment focus
Exhibit 48: Bausch Health - Key offerings
Exhibit 49: F. Hoffmann-La Roche - Overview
Exhibit 50: F. Hoffmann-La Roche - Business segments
Exhibit 51: F. Hoffmann-La Roche - Organizational developments
Exhibit 52: F. Hoffmann-La Roche - Geographic focus
Exhibit 53: F. Hoffmann-La Roche - Segment focus
Exhibit 54: F. Hoffmann-La Roche - Key offerings
Exhibit 55: Sun Pharmaceuticals - Overview
Exhibit 56: Sun Pharmaceuticals - Business segments
Exhibit 57: Sun Pharmaceuticals - Organizational developments
Exhibit 58: Sun Pharmaceuticals - Geographic focus
Exhibit 59: Sun Pharmaceuticals - Segment focus
Exhibit 60: Sun Pharmaceuticals - Key offerings
Exhibit 61: 3M Pharmaceuticals - Overview
Exhibit 62: 3M Pharmaceuticals - Business segments
Exhibit 63: 3M Pharmaceuticals - Organizational developments
Exhibit 64: 3M Pharmaceuticals - Geographic focus
Exhibit 65: 3M Pharmaceuticals - Segment focus
Exhibit 66: 3M Pharmaceuticals - Key offerings
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • 3M Pharmaceuticals
  • Bausch Health
  • F. Hoffmann-La Roche
  • Sun Pharmaceuticals
  • MORE
Global Non-melanoma Skin Cancer Market 2018-2022

The analyst recognizes the following companies as the key players in the global non-melanoma skin cancer market: Bausch Health, F. Hoffmann-La Roche, Sun Pharmaceuticals, and 3M Pharmaceuticals.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the high off-label use of topical treatments for NMSC.”

According to the report, one of the major drivers for this market is the rising incidence of NMSC across the globe, especially in Europe, the US, and Australia.

Further, the report states that one of the major factors hindering the growth of this market is the low data availability on NMSC statistics in cancer registries.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Bausch Health
  • F. Hoffmann-La Roche
  • Sun Pharmaceuticals
  • 3M Pharmaceuticals
Note: Product cover images may vary from those shown
Adroll
adroll